Search Results - "immunogenicity"

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study by Victor Romanenko, Irina Osipova, Anna Galustyan, Michael Scherbakov, Nathalie Baudson, Déborah Farhi, Luis Anaya, Sherine O. Kuriyakose, Nadia Meyer, Winnie Janssens

Connect to this object online.

Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants by Megumi Inoue, Tetsuro Ogawa, Hiroshi Tamura, Yosuke Hagiwara, Yuki Saito, Darren Abbanat, Germie van den Dobbelsteen, Peter Hermans, Stefan Thoelen, Jan Poolman, Patricia Ibarra de Palacios

Connect to this object online.

An mRNA-Based Multiple Antigenic Gene Expression System Delivered by Engineered <i>Salmonella</i> for Severe Fever with Thrombocytopenia Syndrome and Assessment of Its Immunogenicity and Protection Using a Human DC-SIGN-Transduced Mouse Model by Ji-Young Park, Chamith Hewawaduge, Chandran Sivasankar, Khristine Kaith S. Lloren, Byungkwan Oh, Mi Young So, John Hwa Lee

Connect to this object online.

Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis by Shi-Yuan Wang, Jin-Fang Sun, Pei Liu, Li Luo, Jing-Xin Li, Feng-Cai Zhu, Xu-Xiang Shen, Fan-Yue Meng

Connect to this object online.

Reply letter to "Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial" by Sanjay Hadigal, Laura Colombo, Scott Haughie

Connect to this object online.

Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational studyResearch in context by Mangaiarkarasi S. Asokan, Roshni Florina Joan, Sudhir Babji, Girish Dayma, Prajitha Nadukkandy, Vinutha Subrahmanyam, Archana Pandey, Girish Malagi, Pooja Arya, Vibhuti Mahajan, Jayateerth Bhavikatti, Ketakee Pawar, Aishwarya Thorat, Priyanki Shah, Ramakrishna B. Goud, Bishnudeo Roy, Shon Rajukutty, Sushil Immanuel, Dhiraj Agarwal, Sankhanil Saha, Akshatha Shivaraj, Patricia Panikulam, Rajeshwari Shome, Shah-, Anusmrithi U. Sharma, Ajinkya Naik, Shruti Talashi, Madhuri Belekar, Ritu Yadav, Poornima Khude, Mamatha V, Sudarshan Shivalingaiah, Urmila Deshmukh, Chinmayee Bhise, Manjiri Joshi, Leeberk Raja Inbaraj, Sindhulina Chandrasingh, Aurnab Ghose, Colin Jamora, Anandi S. Karumbati, Varadharajan Sundaramurthy, Avita Johnson, Naveen Ramesh, Nirutha Chetan, Chaitra Parthiban, Asma Ahmed, Srabanti Rakshit, Vasista Adiga, George D'souza, Vinay Rale, Carolin Elizabeth George, Jacob John, Anand Kawade, Akanksha Chaturvedi, Anu Raghunathan, Mary Dias, Anand Bhosale, Padinjat Raghu, L.S. Shashidhara, Annapurna Vyakarnam, Vineeta Bal, Gagandeep Kang, Satyajit Mayor

Connect to this object online.

Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial by Ilaria Galgani, Airi Põder, Rain Jõgi, Veli-Jukka Anttila, Stefano Milleri, Alberto M. Borobia, Odile Launay, Marco Testa, Daniela Casula, Luca Grassano, Annaelisa Tasciotti, Marie Dozot, Ashwani K. Arora

Connect to this object online.

Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects. by Sarra Hamrouni, Rachel Bras-Gonçalves, Abdelhamid Kidar, Karim Aoun, Rym Chamakh-Ayari, Elodie Petitdidier, Yasmine Messaoudi, Julie Pagniez, Jean-Loup Lemesre, Amel Meddeb-Garnaoui

Connect to this object online.

Inmunogenicidad y tolerancia de una vacuna contra influenza, en una población mexicana mayor de 55 años de edad Immunogenicity and safety of the influenza vaccine, in a population older than 55-years in Mexico by Octavio Ayala-Montiel, César Mascareñas, Delfino García-Hernández, Jorge Rendón-Muñiz, Irma López, Luis Felipe Montaño

Connect to this object online.

Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years by Enagnon Kazali Alidjinou, Julie Demaret, Bénédicte Corroyer-Simovic, Julien Labreuche, Anne Goffard, Jacques Trauet, Daniela Lupau, Sophie Miczek, Fanny Vuotto, Arnaud Dendooven, Dominique Huvent-Grelle, Juliette Podvin, Daniel Dreuil, Karine Faure, Dominique Deplanque, Laurence Bocket, Alain Duhamel, Annie Sobaszek, Didier Hober, Michael Hisbergues, Francois Puisieux, Brigitte Autran, Yazdan Yazdanpanah, Myriam Labalette, Guillaume Lefèvre

Connect to this object online.

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial by Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon

Connect to this object online.

Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial by Heng Shen, Zhao Wang, Beifang Yang, Kun Cai, Changjun Jiang, Ronghua Xie, Haitao Xiao, Qunhui Ren, Zhengxu Qi, Jinghui Li, Qiong Li, Jianjun Ye, Faxian Zhan

Connect to this object online.

A double-blind, randomized, multicenter, controlled study to evaluate the immunogenicity, safety, and tolerability of varicella vaccine (VARIVAX™) passage extension 34 (PE34) process administered concomitantly with measles, mumps, and rubella vaccine (M-M-R™ II) by Peter E. Silas, Edward N. Zissman, Julie Gardner, Shanjun Helian, Andrew W. Lee, Heather L. Platt

Connect to this object online.

Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule by Federico Martinón-Torres, Ignacio Salamanca de la Cueva, Michael Horn, Soeren Westerholt, Samantha Bosis, Nadia Meyer, Brigitte Cheuvart, Navpreet Virk, Rupert W. Jakes, Maurine Duchenne, Peter Van den Steen

Connect to this object online.

Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study by Paul Martin, Sarah Gleeson, Candice L. Clarke, Tina Thomson, Helena Edwards, Katrina Spensley, Paige Mortimer, Stacey McIntyre, Alison Cox, Graham Pickard, Liz Lightstone, David Thomas, Stephen P. McAdoo, Peter Kelleher, Maria Prendecki, Michelle Willicombe

Connect to this object online.

Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age by Anna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, Delia Caparas-Yu, Astrid Greijer, Michel Duchene, Gert Scheper, Vitalija van Paassen, Mathieu Le Gars, Conor P. Cahill, Hanneke Schuitemaker, Macaya Douoguih, Jeanne-Marie Jacquet

Connect to this object online.

Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study by Shanshan Li, Xiaojie Wu, Nanyang Li, Guoying Cao, Jingjing Wang, Yuancheng Chen, Size Li, Jinjie He, Jufang Wu, Haijing Yang, Ke Lin, Chao Qiu, Angela Liu, He Zhou, Francisco Adrian, Liang Schweizer, Wenhong Zhang, Jingwen Gu, Jing Zhang, Jing Zhang

Connect to this object online.

A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR) by Alvino Maestri, Su Eun Park, Fiona Fernandes, Zhongyi "Lucy" Li, Yae-Jean Kim, Yun-Kyung Kim, Jin Lee, Ji Young Park, Dong Hyun Kim, GyongSeon Yang, Hyunjung Lim, Jin Oh Kim, Robert Lupinacci, Tina M. Sterling, Marissa Wilck, Alejandra Esteves-Jaramillo, Natalie Banniettis

Connect to this object online.

Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study by Martina Kovac, Lusiné Kostanyan, Narcisa Mesaros, Sherine Kuriyakose, Meera Varman

Connect to this object online.

Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers<subtitle>A pooled analysis of randomized trials</subtitle> by Kristina A. Bryant, Jodie McVernon, Colin D. Marchant, Terry Nolan, Gary S. Marshall, Peter Richmond, Helen Marshall, Michael Nissen, Stephen B. Lambert, Emmanuel Aris, Narcisa Mesaros, Jacqueline M. Miller

Connect to this object online.